Drug intelligence / Profile preview

Wangbi

Development stage
Phase 4
Lead developer
Liaoning Good Nurse Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Wangbi is a traditional Chinese medicine (TCM) herbal formula used primarily in China for the treatment of rheumatoid arthritis and osteoarthritis. It is available in several formulations including granules, tablets, and capsules. The preparation contains a combination of 16 herbal ingredients such as Radix Rehmanniae, Radix aconiti lateralis preparata, Rhizoma Drynariae, Cassia Twig, Epimedium brevicornu Maxim., Carthami Flos, goat bone and others[3][5]. Wangbi exerts anti-inflammatory and immunomodulatory effects by regulating key inflammatory pathways including PI3K-Akt signaling and NF-κB activation[2][3][4][5][6]. It reduces the expression of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and modulates immune response genes associated with joint inflammation and bone destruction[2][4][5]. Clinical studies have shown that it can alleviate symptoms like joint pain/swelling in rheumatoid arthritis or knee osteoarthritis patients who do not achieve full remission with standard therapies like methotrexate or tofacitinib[1][7]. The product has been approved by the China Food and Drug Administration for use in rheumatoid arthritis. Its mechanism involves multi-target regulation of immunity-inflammation imbalance as well as antioxidant effects during acute phases of disease[2].

Brand names
WangbiWangbi granuleWang-Bi tabletWang-Bi capsule
Other names
王痹 (Chinese)WBT (abbreviation for Wang-Bi tablet)WB (abbreviation for Wang-Bi capsule)
02

Targets

IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))NF-κBIL-6 (Interleukin 6)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on Wangbi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wangbi.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call